Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10635)
All Articles published online
|
Publishing Process of This Article
|
Jun 21, 2019 (publication date) through Jul 12, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yang F, Jin C, Fu DL, Warshaw AL. Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges. World J Gastroenterol 2019; 25(23): 2839-2845 [PMID: 31249443 DOI: 10.3748/wjg.v25.i23.2839] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i23/2839.htm |
| Number | Citing Articles |
| 1 |
Ruchi Singhal, Sherise C Rogers, Ji-Hyun Lee, Brian Ramnaraign, Ilyas Sahin, Jesus C Fabregas, Ryan M. Thomas, Steven J Hughes, Ibrahim Nassour, Kathryn Hitchcock, Karen Russell, Omar Kayaleh, Anita Turk, Robert Zlotecki, David L DeRemer, Thomas J George. A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. Future Oncology 2023; 19(27): 1843 doi: 10.2217/fon-2023-0256
|
| 2 |
Xiangsheng Liu, Jinhong Jiang, Yu‐Pei Liao, Ivanna Tang, Emily Zheng, Waveley Qiu, Matthew Lin, Xiang Wang, Ying Ji, Kuo‐Ching Mei, Qi Liu, Chong Hyun Chang, Zev A. Wainberg, Andre E. Nel, Huan Meng. Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1. Advanced Science 2021; 8(6) doi: 10.1002/advs.202002147
|
| 3 |
Antonio Galvano, Marta Castiglia, Sergio Rizzo, Nicola Silvestris, Oronzo Brunetti, Giovanni Vaccaro, Valerio Gristina, Nadia Barraco, Marco Bono, Giovanni Guercio, Giuseppa Graceffa, Fabio Fulfaro, Stefania Gori, Viviana Bazan, Antonio Russo. Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. Cancers 2020; 12(3): 534 doi: 10.3390/cancers12030534
|
| 4 |
Jae Yun Jung, Hyun Jin Ryu, Seung-Hwan Lee, Dong-Young Kim, Myung Ji Kim, Eun Ji Lee, Yeon-Mi Ryu, Sang-Yeob Kim, Kyu-Pyo Kim, Eun Young Choi, Hyung Jun Ahn, Suhwan Chang. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model. Cells 2021; 10(10): 2734 doi: 10.3390/cells10102734
|
| 5 |
TUĞBA AKMAN YILDIZ, EMEK KÖSE, SAMANTHA L. ELLIOTT. MATHEMATICAL MODELING OF PANCREATIC CANCER TREATMENT WITH CANCER STEM CELLS. Journal of Biological Systems 2021; 29(04): 799 doi: 10.1142/S0218339021500182
|
| 6 |
Taylor J. Allen-Coyle, Jin Niu, Eva Welsch, Neil T. Conlon, Weylon Garner, Martin Clynes, Finbarr O’Sullivan, Robert M. Straubinger, Donald E. Mager, Sandra Roche. FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures. The AAPS Journal 2022; 24(6) doi: 10.1208/s12248-022-00752-8
|
| 7 |
Richard Drexler, Kim C. Wagner, Mirco Küchler, Bernd Feyerabend, Moritz Kleine, Karl J. Oldhafer. Significance of unphosphorylated and phosphorylated heat shock protein 27 as a prognostic biomarker in pancreatic ductal adenocarcinoma. Journal of Cancer Research and Clinical Oncology 2020; 146(5): 1125 doi: 10.1007/s00432-020-03175-0
|
| 8 |
Shintaro Fumoto, Koyo Nishida. Co-delivery Systems of Multiple Drugs Using Nanotechnology for Future Cancer Therapy. Chemical and Pharmaceutical Bulletin 2020; 68(7): 603 doi: 10.1248/cpb.c20-00008
|